


Healthcare News Roundup: Biopharmaceuticals
HSMN NewsFeed - 25 Jun 2025
Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735
Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735
HSMN NewsFeed - 16 Jun 2025
Solu Therapeutics Appoints Enda Moran, PhD, MBA as Chief Operating Officer
Solu Therapeutics Appoints Enda Moran, PhD, MBA as Chief Operating Officer
HSMN NewsFeed - 23 May 2025
England's NICE Recommends FILSPARI(R) (sparsentan) as a Treatment Option for IgA Nephropathy
England's NICE Recommends FILSPARI(R) (sparsentan) as a Treatment Option for IgA Nephropathy
HSMN NewsFeed - 16 May 2025
BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma
BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma
HSMN NewsFeed - 13 May 2025
Hansa Biopharma appoints Maria Törnsén as Chief Operating Officer and President U.S.
Hansa Biopharma appoints Maria Törnsén as Chief Operating Officer and President U.S.
